WGS

WGS

USD

GeneDx Holdings Corp. Class A Common Stock

$139.485+4.575 (3.391%)

实时价格

Healthcare
Diagnostics & Research
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$134.910

最高价

$141.750

最低价

$134.000

成交量

0.68M

公司基本面

市值

4.0B

所属行业

Diagnostics & Research

国家/地区

United States

交易统计

平均成交量

0.58M

交易所

NMS

货币

USD

52周价格范围

最低价 $55.17当前价 $139.485最高价 $146

相关新闻

Analyst Upgrades

Wells Fargo Maintains Equal-Weight on GeneDx Holdings, Raises Price Target to $140

Wells Fargo analyst Brandon Couillard maintains GeneDx Holdings with a Equal-Weight and raises the price target from $95 to $140.

查看更多
Wells Fargo Maintains Equal-Weight on GeneDx Holdings, Raises Price Target to $140
Analyst Upgrades

Canaccord Genuity Maintains Buy on GeneDx Holdings, Raises Price Target to $160

Canaccord Genuity analyst Kyle Mikson maintains GeneDx Holdings with a Buy and raises the price target from $155 to $160.

查看更多
Canaccord Genuity Maintains Buy on GeneDx Holdings, Raises Price Target to $160
Analyst Upgrades

Guggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $170

Guggenheim analyst Subbu Nambi maintains GeneDx Holdings with a Buy and raises the price target from $115 to $170.

查看更多
Guggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $170
Analyst Upgrades

BTIG Maintains Buy on GeneDx Holdings, Raises Price Target to $165

BTIG analyst Mark Massaro maintains GeneDx Holdings with a Buy and raises the price target from $140 to $165.

查看更多
BTIG Maintains Buy on GeneDx Holdings, Raises Price Target to $165
BusinessWire

GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights

Reported third quarter 2025 revenues of $116.7 million with 65% year-over-year growth in exome and genome test revenue Accelerated exome and genome volume growth to 33% year-over-year Expanded adjusted gross

查看更多
GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights
PR Newswire

GeneDx Holdings Corp. (NASDAQ: WGS) Investor Reminder: Schubert Jonckheer Investigating Possible False Claims

Schubert Jonckheer & Kolbe LLP reminds GeneDx Holdings Corp. (NASDAQ: WGS) investors that the firm is investigating potential legal claims relating...

Analyst Upgrades

BTIG Maintains Buy on GeneDx Holdings, Raises Price Target to $140

BTIG analyst Mark Massaro maintains GeneDx Holdings with a Buy and raises the price target from $125 to $140.